Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SNDX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Revumenib (SNDX-5613) FDA approved Nov 2024 · Revuforj |
Acute Myeloid Leukemias | Phase 3 · NCT07211958 | Recruiting |
| Axatilimab (SNDX-6352) FDA approved Aug 2024 · Niktimvo |
Chronic Graft-versus-host-disease | Phase 2 · NCT04710576 | Recruiting |
| Gilteritinib | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
| Daunorubicin | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
| Daunorubicin or Idarubicin (BAML-16-001-S25/HO18… | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
| Ivosidenib (AG-120) | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
| Entospletinib | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
| Ficlatuzumab | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
| Intensive Chemotherapy Regimen | Acute Myeloid Leukemias | Phase 3 · NCT07211958 | Recruiting |
| Pevonedistat | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
| Samalizumab | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
| Dubermatinib (TP-0903) | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
| Lomonitinib | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
| Enasidenib (AG-221) | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
| Bivalent BRD4 Inhibitor AZD5153 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
| Mcl-1 Inhibitor AZD5991 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2/3 · NCT03013998 | Recruiting |
Also used in these trials (approved or third-party drugs, not SNDX's own candidates): Cytarabine, Decitabine, Venetoclax, Azacitidine, Avelumab, Momelotinib, Nivolumab, Pembrolizumab, Cobicistat, Anastrozole, Atezolizumab, Ruxolitinib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SNDX holds $551.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $28.8M/quarter from operations, an estimated runway of 57.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SNDX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 9,268,460 | 10.38% | 2026-09-30 |
| Kynam Capital Management, LP | Institution (13F) | 8,150,959 | 9.13% | 2026-09-30 |
| Goldman Sachs Group Inc | Institution (13F) | 5,523,284 | 6.19% | 2026-09-30 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 4,653,172 | 5.21% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 4,457,143 | 4.99% | 2026-03-31 |
| Bank of America Corporation | Institution (13F) | 3,801,955 | 4.26% | 2026-09-30 |
| Deerfield Management Company, L.P | Institution (13F) | 3,779,900 | 4.23% | 2026-09-30 |
| Franklin Resources, Inc. | Institution (13F) | 3,485,448 | 3.90% | 2026-09-30 |
| Franklin Templeton, Inc. | Institution (13F) | 3,485,448 | 3.90% | 2026-09-30 |
| Hood River Capital Management LLC | Institution (13F) | 2,596,543 | 2.91% | 2026-09-30 |
| Eversept Partners, LP | Institution (13F) | 2,443,056 | 2.74% | 2026-09-30 |
| Michael A Metzger Chief Executive Officer, Director · +804,000 options |
Insider | 484,843 | 0.54% | 2026-07-08 |
Share count 89,297,086 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-09 filed 2026-11-12 |
Ondrey Aaron |
Option award (A) | 270,000 | $9.55 | – |
| 2026-10-29 filed 2026-10-30 |
Podlesak Dennis |
Option exercise (M) | 8,000 | $11.81 | 247,763 |
| 2026-10-29 filed 2026-10-30 |
Podlesak Dennis |
Sale (S) | 8,000 | $14.21 | 239,763 |
| 2026-10-29 filed 2026-10-30 |
Podlesak Dennis |
Option exercise (M) | 8,000 | – | – |
| 2026-07-08 filed 2026-07-09 |
Metzger Michael A |
Sale (S) | 32,375 | $24.24 | 484,843 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-10-25 | Revuforj | sNDA | -10% | -3.1% | +1.3% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SNDX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →